Gambro ends Japanese joint venture to sell independently
This article was originally published in Clinica
Swedish company Gambro is to go it alone in Japan, having broken off its sales joint venture with Teijin Medical in the second largest dialysis market after the US. As a result, Gambro will lose revenues of SEK200 million ($24 million), although it says the impact on profits will be insignificant. The joint venture, Gambro Teijin Medical, will be dissolved in December, by mutual agreement.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.